Literature DB >> 23100963

Recombinant factor VIIa: use in fatal post partum hemorrhage - Indian experience case series and review of literature.

Shailesh R Singi1, Evita Fernandez, Sunil T Pandya, H R Badrinath.   

Abstract

Postpartum hemorrhage is leading cause of maternal mortality and still remains a challenging condition to treat and hysterectomy may be required to control the bleeding once medical interventions fail. These strategies are not always successful and a direct approach in activating the coagulation system can be more effective and life saving. We describe here the mechanism of action of rFVIIa, review of literature and its use in 10 cases with different causes for PPH with good response.

Entities:  

Keywords:  Bleeding; Coagulation; Hemorrhage; NICE registry; NovoSeven; PPH; rFVIIa

Year:  2009        PMID: 23100963      PMCID: PMC3453477          DOI: 10.1007/s12288-009-0001-y

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  17 in total

1.  Treatment of traumatic bleeding with recombinant factor VIIa.

Authors:  G Kenet; R Walden; A Eldad; U Martinowitz
Journal:  Lancet       Date:  1999-11-27       Impact factor: 79.321

2.  Use of recombinant factor VIIa for massive postpartum haemhorrage: case series and review of literature.

Authors:  Tahir Sultan Shamsi; Nazli Hossain; Nargis Soomro; Jahan Ara Hasan; Mehar Noorani; Sara Kazi; Mohammed Saeed Quraishy; Bilal Jameel; Syed Tipu Sultan; Saeeda Haider
Journal:  J Pak Med Assoc       Date:  2005-11       Impact factor: 0.781

3.  Recombinant factor VIIa: a universal haemostatic agent?

Authors:  Ravi Gill; Mike Herbertson
Journal:  Ann Card Anaesth       Date:  2006-07

4.  Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile.

Authors:  Jerrold H Levy; Abe Fingerhut; Thomas Brott; Irene H Langbakke; Elisabeth Erhardtsen; Robert J Porte
Journal:  Transfusion       Date:  2006-06       Impact factor: 3.157

5.  Pregnancy-related mortality in the United States due to hemorrhage: 1979-1992.

Authors:  L O Chichakli; H K Atrash; A P MacKay; A S Musani; C J Berg
Journal:  Obstet Gynecol       Date:  1999-11       Impact factor: 7.661

6.  Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII.

Authors:  F Moscardó; F Pérez; J de la Rubia; B Balerdi; J I Lorenzo; M L Senent; I Aznar; S Carceller; M A Sanz
Journal:  Br J Haematol       Date:  2001-07       Impact factor: 6.998

7.  Recombinant activated factor VII for adjunctive hemorrhage control in trauma.

Authors:  U Martinowitz; G Kenet; E Segal; J Luboshitz; A Lubetsky; J Ingerslev; M Lynn
Journal:  J Trauma       Date:  2001-09

Review 8.  Mechanism of action of factor VIIa in the treatment of coagulopathies.

Authors:  Ulla Hedner
Journal:  Semin Thromb Hemost       Date:  2006-04       Impact factor: 4.180

Review 9.  The use of recombinant factor VIIa in the treatment of bleeding disorders.

Authors:  Harold R Roberts; Dougald M Monroe; Gilbert C White
Journal:  Blood       Date:  2004-08-24       Impact factor: 22.113

10.  Successful treatment of life-threatening postpartum hemorrhage with recombinant activated factor VII.

Authors:  Frank W Bouwmeester; Andries R Jonkhoff; René H M Verheijen; Herman P van Geijn
Journal:  Obstet Gynecol       Date:  2003-06       Impact factor: 7.661

View more
  2 in total

1.  Blood transfusion practice in obstetric and gynecology: impact of educational programs to create awareness for judicious use of blood components.

Authors:  Snehalata C Gupte; Pratima N Patel
Journal:  Indian J Hematol Blood Transfus       Date:  2013-01-24       Impact factor: 0.900

Review 2.  Rational Use of Recombinant Factor VIIa in Clinical Practice.

Authors:  T K Dutta; S P Verma
Journal:  Indian J Hematol Blood Transfus       Date:  2013-02-23       Impact factor: 0.900

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.